Assetmark Inc. Boosts Stock Position in Outset Medical, Inc. (NASDAQ:OM)

Assetmark Inc. raised its stake in Outset Medical, Inc. (NASDAQ:OMGet Rating) by 49.7% during the 3rd quarter, Holdings Channel.com reports. The firm owned 2,712 shares of the company’s stock after buying an additional 900 shares during the quarter. Assetmark Inc.’s holdings in Outset Medical were worth $43,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in OM. Point72 Hong Kong Ltd acquired a new stake in Outset Medical in the second quarter worth about $27,000. Nisa Investment Advisors LLC boosted its holdings in Outset Medical by 139.5% in the second quarter. Nisa Investment Advisors LLC now owns 2,060 shares of the company’s stock worth $31,000 after acquiring an additional 1,200 shares in the last quarter. US Bancorp DE boosted its holdings in Outset Medical by 56.6% in the third quarter. US Bancorp DE now owns 4,068 shares of the company’s stock worth $65,000 after acquiring an additional 1,471 shares in the last quarter. Quantbot Technologies LP boosted its holdings in Outset Medical by 48.6% in the second quarter. Quantbot Technologies LP now owns 9,779 shares of the company’s stock worth $145,000 after acquiring an additional 3,197 shares in the last quarter. Finally, Perpetual Investment Management Ltd acquired a new stake in Outset Medical in the second quarter worth about $163,000. Hedge funds and other institutional investors own 98.84% of the company’s stock.

Outset Medical Stock Up 0.2 %

Shares of OM stock opened at $27.06 on Monday. The stock has a 50 day moving average of $23.58 and a 200 day moving average of $19.25. The company has a current ratio of 6.24, a quick ratio of 5.13 and a debt-to-equity ratio of 0.11. The stock has a market cap of $1.31 billion, a P/E ratio of -7.91 and a beta of 1.50. Outset Medical, Inc. has a twelve month low of $11.41 and a twelve month high of $48.71.

Outset Medical (NASDAQ:OMGet Rating) last announced its quarterly earnings results on Tuesday, November 8th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.03). The company had revenue of $27.76 million for the quarter, compared to analysts’ expectations of $25.35 million. Outset Medical had a negative net margin of 145.93% and a negative return on equity of 49.75%. As a group, sell-side analysts expect that Outset Medical, Inc. will post -3.43 EPS for the current year.

Insider Activity

In other news, CEO Leslie Trigg sold 30,000 shares of the business’s stock in a transaction that occurred on Friday, November 11th. The stock was sold at an average price of $20.00, for a total value of $600,000.00. Following the completion of the sale, the chief executive officer now directly owns 291,159 shares in the company, valued at $5,823,180. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, COO Martin Vazquez sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $26.14, for a total value of $130,700.00. Following the completion of the sale, the chief operating officer now directly owns 49,290 shares in the company, valued at $1,288,440.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Leslie Trigg sold 30,000 shares of the business’s stock in a transaction that occurred on Friday, November 11th. The stock was sold at an average price of $20.00, for a total value of $600,000.00. Following the sale, the chief executive officer now owns 291,159 shares of the company’s stock, valued at $5,823,180. The disclosure for this sale can be found here. Insiders sold 129,810 shares of company stock worth $2,816,218 over the last three months. 4.00% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

OM has been the subject of a number of research reports. Cowen decreased their target price on Outset Medical to $22.00 in a report on Tuesday, November 15th. Cowen decreased their target price on Outset Medical from $33.00 to $22.00 in a report on Wednesday, November 9th. The Goldman Sachs Group decreased their target price on Outset Medical from $34.00 to $29.00 and set a “buy” rating for the company in a report on Wednesday, November 9th. Morgan Stanley lifted their target price on Outset Medical from $17.00 to $27.00 and gave the stock an “equal weight” rating in a report on Friday, January 6th. Finally, Royal Bank of Canada initiated coverage on Outset Medical in a report on Friday, November 11th. They set an “outperform” rating and a $23.00 target price for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.50.

Outset Medical Profile

(Get Rating)

Outset Medical, Inc, a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings.

Featured Stories

Want to see what other hedge funds are holding OM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Outset Medical, Inc. (NASDAQ:OMGet Rating).

Institutional Ownership by Quarter for Outset Medical (NASDAQ:OM)

Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.com's FREE daily email newsletter.